Aster Pharmacy, Dr. Reddy’s to market medicines in UAE and GCC
Now Reading
Aster Pharmacy, Dr. Reddy’s to market medicines in UAE and GCC

Aster Pharmacy, Dr. Reddy’s to market medicines in UAE and GCC

Prescription medicines to be distributed across therapy areas like gastroenterology, pain management, cardiovascular disease and antihistamines

Gulf Business

Aster Pharmacy, the retail arm of Aster DM Healthcare, and Dr. Reddy’s laboratories India, a global pharmaceutical company headquartered in Hyderabad, India, have signed an agreement to make affordable and quality medication easily accessible in the region.

Under the agreement, Dr. Reddy’s will manufacture and supply certain medications in the identified therapy areas to Alfa One, the marketing and distribution arm of Aster Pharmacy. The drugs will be distributed all over UAE and GCC by Alfa One.

Dr Azad Moopen, founder chairman and MD, Aster DM Healthcare, said, “Aster believes in bringing the best medical care to the people we serve through our healthcare services and products. As medicines play a very important role in the delivery of quality healthcare at an affordable cost, we think that a collaboration with reputed pharmaceutical manufacturers will tremendously help in achieving this. The partnership with renowned Pharma major Dr. Reddy’s Lab from India is a step-forward towards making branded generics of international repute available in the GCC region.”

“At Aster, we serve almost 20 million patients each year and providing the best care as per their needs is our purpose. As such, innovation, diversification and ensuring affordable access to the best healthcare solutions are core to our strategy. Aster Pharmacy was incepted more than two decades ago and is constantly expanding its footprint as well as its product portfolio to meet the needs of our customers. With Dr. Reddy’s diverse product offerings and expertise in generics, we believe this partnership is all set to strengthen the healthcare sector in the region,” said Alisha Moopen, Deputy Managing Director, Aster DM Healthcare.

Deepak Sapra, CEO – API and Services, Dr. Reddy’s Laboratories India Ltd said: “We have had a close business relationship with the UAE and GCC. We value this opportunity to serve more patients in the region with our high-quality and trusted products. As a vertically integrated company, Dr. Reddy’s will manufacture the active pharmaceutical ingredient (API) as well as the formulation in-house at its facilities. The APIs will be manufactured at facilities approved by the regulatory authorities of the US, Europe and other highly-regulated markets. By combining our manufacturing strengths with the marketing and distribution strengths of a strong partner such as Aster, we will be able to take strides towards our goal of reaching over 1.5 billion patients by 2030.”

 Read: Aster Pharmacy, talabat UAE announce partnership to deliver prescription medicines

You might also like


Scroll To Top